[Cost-effectiveness of hepatitis C treatment in slow virologic responders coinfected with HIV].

No abstract is available for this paper.

• Publication year

  2013

• Venue

  Cadernos de Saúde Pública

• Publication date

  Unknown publication date

• Fields of study

  Medicine, Economics

• Identifiers
  PMID 25402243
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Avaliação Econômica do Interferon Peguilado Alfa 2a em Combinação com a Ribavirina para o Tratamento da Infecção Pelo Genótipo 1 da Hepatite Crônica C: Comparação do Tratamento por 48 Semanas e Terapia Estendida

  2013cited by this paper
• Extended Therapy With Pegylated Interferon and Weight-Based Ribavirin for HCV-HIV Coinfected Patients

  2012cited by this paper
• PGI23 Cost Effectiveness of Retreatment of Patients with Chronic Hepatitis C (Chc) Who Do Not Respond to Peginterferon Alpha and Ribavirin for 48 Weeks Vs. Peginterferon Alfa and Ribavirin for 72 Weeks

  2012cited by this paper
• Economic burden of hepatitis C-associated diseases: Europe, Asia Pacific, and the Americas

  2012cited by this paper
• Influence of HCV genotype 1 subtypes on the virus response to PEG interferon alpha‐2a plus ribavirin therapy

  2011cited by this paper
• Alfapeguinterferon-2a e ribavirina versus alfapeguinterferon-2b e ribavirina: avaliação custo-efetividade e do impacto orçamentário do tratamento do genótipo 1 da hepatite C crônica

  2011cited by this paper
• Response‐guided peg‐interferon plus ribavirin treatment duration in chronic hepatitis C: Meta‐analyses of randomized, controlled trials and implications for the future

  2011cited by this paper
• EASL Clinical Practice Guidelines: management of hepatitis C virus infection.

  2011cited by this paper
• Da excepcionalidade às linhas de cuidado: o componente especializado da assistência farmacêutica

  2010cited by this paper
• Barriers to treatment of hepatitis C in HIV/HCV coinfected adults in Brazil.

  2010cited by this paper
• Peginterferon Plus Ribavirin for Chronic Hepatitis C in Patients With Human Immunodeficiency Virus

  2009cited by this paper
• Cost effectiveness of peginterferon alfa-2B combined with ribavirin for the treatment of chronic hepatitis C in Brazil.

  2009cited by this paper
• Randomized trial comparing pegylated interferon α‐2b versus pegylated interferon α‐2a, both plus ribavirin, to treat chronic hepatitis C in human immunodeficiency virus patients

  2009cited by this paper
• Co-infecção por HIV/HCV em hospital universitário de Recife, Brasil

  2009cited by this paper
• [HIV/HCV coinfection at an university hospital in Recife, Brazil].

  2009cited by this paper
• Avaliação da efetividade do tratamento de pacientes co-infectados HCV-HIV com as terapias combinadas interferon + ribavirina e peginterferon + ribavirina

  2008cited by this paper
• Health-state utilities in liver disease: a systematic review.

  2008cited by this paper
• Economic impact of extended treatment with peginterferon α‐2a and ribavirin for slow hepatitis C virologic responders

  2008cited by this paper
• Cost-effectiveness of treatment for hepatitis C in an urban cohort co-infected with HIV.

  2007cited by this paper
• Risk factors for liver transplantation waiting list mortality

  2007cited by this paper
• Role of Weight-Based Ribavirin Dosing and Extended Duration of Therapy in Chronic Hepatitis C in HIV-Infected Patients: The PRESCO Trial

  2007cited by this paper
• Co-infecção HIV/HCV em pacientes de Botucatu e região

  2007cited by this paper
• Extended treatment duration for hepatitis C virus type 1: comparing 48 versus 72 weeks of peginterferon-alfa-2a plus ribavirin.

  2006cited by this paper
• Peginterferon-alfa2a plus ribavirin for 48 versus 72 weeks in patients with detectable hepatitis C virus RNA at week 4 of treatment.

  2006cited by this paper
• Economic burden of hepatitis C in Canada and the potential impact of prevention

  2005cited by this paper
• Results of a Study of Prolonging Treatment with Pegylated Interferon-α2A plus Ribavirin in HIV/HCV-Coinfected Patients with No Early Virological Response

  2005cited by this paper
• Peginterferon Alfa-2a plus ribavirin for chronic hepatitis C virus infection in HIV-infected patients.

  2004cited by this paper
• Peginterferon Alfa-2a plus ribavirin versus interferon alfa-2a plus ribavirin for chronic hepatitis C in HIV-coinfected persons.

  2004cited by this paper
• CD4 Cell Response to 3 Doses of Subcutaneous Interleukin 2: Metaanalysis of 3 Vanguard Studies

  2004cited by this paper
• Making Choices in Health: WHO Guide to Cost Effectiveness Analysis

  2003cited by this paper
• Treatment for hepatitis C virus in human immunodeficiency virus-infected patients: clinical benefits and cost-effectiveness.

  2002cited by this paper
• Cost Effectiveness in Health and Medicine.

  1998cited by this paper
• Estimates of the Cost-Effectiveness of a Single Course of Interferon-2b in Patients with Histologically Mild Chronic Hepatitis C

  1997cited by this paper
• Human immunodeficiency virus infection modifies the natural history of chronic parenterally-acquired hepatitis C with an unusually rapid progression to cirrhosis.

  1997cited by this paper
• European Association for the Study of the Liver

  1971cited by this paper

• Cost-Effectiveness of Resmetirom for Metabolic Dysfunction-Associated Steatohepatitis in Brazil.

  2025cites this paper
• Chronic Hepatitis C: An Overview of Evidence on Epidemiology and Management from a Brazilian Perspective

  2015cites this paper